<b>Background/Objectives</b>: Precise intracellular delivery of chemotherapeutics remains a major challenge in HER2-positive breast cancer, where intratumoral heterogeneity and limited tissue penetration constrain efficacy. The gene discussed is ERBB2; the disease is breast carcinoma.